Table 1.
Patient characteristics
| n = 29 | |
|---|---|
| Age in years, median (range) | 73 (45–86) |
| Male sex, n (%) | 19 (65.5%) |
| Histology, n (%) | |
| Adeno | 16 (55.1%) |
| Squamous | 8 (27.6%) |
| NSCLC | 5 (17.2%) |
| PD‐L1 TPS, n (%) | |
| 0% | 10 (34.5%) |
| 1–49% | 8 (27.6%) |
| ≥50%, n (%) | 11 (37.9%) |
| Driver mutation, n (%) | |
| EGFR | 5 (17.2%) |
| ALK | 2 (7.0%) |
| Stage, n (%) | |
| I | 5 (17.2%) |
| II | 3 (10.3%) |
| III | 10 (34.5%) |
| IV | 11 (37.9%) |
Adeno, adenocarcinoma; NSCLC, non‐small cell lung cancer; PD‐L1, programmed death‐ligand 1; Squamous, squamous cell carcinoma; TPS, tumor proportion score.